Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis

NCT06465810 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT06465810
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06465810 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients With Transthyretin (ATTR) Amyloidosis
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Recruiting
Start date
June 25, 2024
Completion date
December 31, 2031
Enrollment
1,850 (estimated)
Sites
89

Conditions

As the registry lists them; a condition with its own page is linked.

attr, attr-cm, attr-mixed, attrv-pn, hattr, transthyretin amyloidosis